Key result
Microalbuminuria is a strong marker for cardiovascular and renal risk, but routine testing is currently recommended only for high-risk patients with diabetes or chronic kidney disease.
A roundtable discussion summarizing the relationship between hypertension, renal disease, and cardiovascular outcomes.
Supports targeted testing in diabetes and CKD; leaves open whether routine screening improves outcomes in broader hypertension populations.
During the meeting of the American Society of Hypertension in San Francisco, CA on May 17, 2005, a roundtable was convened to discuss the relationship between hypertension, renal disease, and cardiovascular outcomes. Dr. Marvin Moser, Clinical Professor at Yale University School of Medicine, New Haven, CT, chaired the session. Dr. Jan Basile, Professor of Medicine at the Ralph Johnson VA Medical Center and the Medical University of South Carolina in Charleston, SC and Dr. William Cushman, Professor of Preventive Medicine and Medicine at the University of Tennessee in Memphis, TN participated in the discussion.
No takes yet. Share an insight, caveat, or question.
Moser et al. (2005) studied Hypertension and Renal Disease. Microalbuminuria is a strong marker for cardiovascular and renal risk, but routine testing is currently recommended only for high-risk patients with diabetes or chronic kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: